We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
All medicines included in the Australian Register of Therapeutic Goods (ARTG) must include the relevant AUST number (either AUST R, AUST L or AUST L(A) number) on the label.
What is the AUST number?
The AUST number identifies the product on the ARTG. It is also known as the ARTG ID or the registration or listing number.
The AUST number gives consumers and health professionals confidence that the medicine has been approved (registered or listed) by the TGA for supply in Australia. Medicines with AUST R and AUST L(A) are assessed for efficacy, while those with AUST L are not.
See How we regulate medicines for more information about the different types of medicines and their AUST numbers.
Medicine labels without an AUST number
The TGA administers various pathways that allow access to medicines that are not included in the ARTG (considered 'unapproved'). Medicines accessed under these pathways will not have an AUST R, L or L(A) number on the label.
If a medicine does not have an AUST number on the label and has not been accessed under one of these pathways it may have been supplied illegally. Examples of pathways that may allow supply of products without an AUST number can be found on our Accessing 'unapproved' products webpage.
Outside these access pathways, only in extraordinary circumstances will an ARTG medicine not include the AUST number on the label.
Medicines on the ARTG without the AUST number on the label
Section 19D of the Therapeutic Goods Act 1989 permits the Secretary (or the Secretary's delegate) to consent to the importation or supply of a TGA approved medicine without the relevant AUST number on the primary pack label.
Extraordinary circumstances
Consent for a medicine on the ARTG to be imported or supplied without the AUST number on the label will only be considered in extraordinary circumstances. TGA will inform sponsors where it may be appropriate for consent to be granted.
Consent would only be considered in situations where including the AUST number on the label of a medicine (either by printing or over-stickering) presents an unusual and unexpected challenge and immediate or timely supply of the medicine would address a national public health emergency, such as a pandemic declared by the World Health Organization (WHO).
Consent under section 19D can only be given to an Australian approved product (that is, not an overseas substitute product to address a medicine shortage), limited to a short period of time. Where consent has been provided, the sponsor of the medicine would also need to widely circulate the product's AUST number to health practitioners and consumers.
Note that consent under section 19D of the Act does not remove the need for the medicine to meet other Australian labelling requirements, such as the labelling Therapeutic Goods Orders and requirements under the Poisons Standard.
Legislative basis
Regulation 15 of the Therapeutic Goods Regulations 1990 outlines the requirements for including the AUST number on a medicine label.
Subsections 19D(3) and 19D(4) of the Therapeutic Goods Act 1989 provides civil penalties for importing or supplying registered or listed medicines without the relevant AUST number on the label in the absence of consent.
Where consent is given to import or supply an Australian medicine without the AUST number, details of the decision must be published on the website. If consent is not given under section 19D of the Act, the applicant must be informed within 28 days of the decision to refuse and the reasons for the refusal.
Medicines with consent for import or supply without the AUST number on the label
TGA has given consent for the following medicines to be imported or supplied without the AUST number on the label.
LAGEVRIO molnupiravir 200 mg capsules bottle
AUST number: 372650
Prescription medicine
Sponsor: Merck Sharp & Dohme (Australia) Pty Ltd
Supply/import: Import and supply
Indication (abridged) Treatment of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.
Duration of consent: All batches of the product imported or supplied until 29 February 2024.
Reason for consent: Availability of the product for importation and supply in Australia as soon as possible will assist in the management of the COVID-19 pandemic in Australia, and the preparation and application of labels for the product that set out the registration number would delay the timely availability of the product in Australia for that purpose. Accordingly, this consent will assist in facilitating the timely availability of the product in Australia and is therefore necessarily in the public interest.
PAXLOVID nirmatrelvir 150 mg tablet and ritonavir 100 mg tablet blister composite pack
AUST number: 377572
Prescription medicine
Sponsor: Pfizer Australia Pty Ltd
Supply/import: Import and supply
Indication (abridged) Treatment of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.
Duration of consent: All batches of the product imported or supplied until 30 June 2024.
Reason for consent: Availability of the product for importation and supply in Australia as soon as possible will assist in the management of the COVID-19 pandemic in Australia, and the preparation and application of labels for the product that set out the registration number would delay the timely availability of the product in Australia for that purpose. Accordingly, this consent will assist in facilitating the timely availability of the product in Australia and is therefore necessarily in the public interest.
PAXLOVID nirmatrelvir 150 mg tablet and ritonavir 100 mg tablet blister composite pack
AUST number: 389801
Prescription medicine
Sponsor: Pfizer Australia Pty Ltd
Supply/import: Import and supply
Indication (abridged) Treatment of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.
Duration of consent: All batches of the product imported or supplied until 30 June 2024.
Reason for consent: Availability of the product for importation and supply in Australia as soon as possible will assist in the management of the COVID-19 pandemic in Australia, and the preparation and application of labels for the product that set out the registration number would delay the timely availability of the product in Australia for that purpose. Accordingly, this consent will assist in facilitating the timely availability of the product in Australia and is therefore necessarily in the public interest.
COMIRNATY Omicron XBB.1.5 (raxtozinameran) COVID-19 VACCINE 30 micrograms/0.3 mL suspension for injection multidose vial
AUST number: 419330
Prescription medicine
Sponsor: Pfizer Australia Pty Ltd
Supply/import: Import and supply
Indication (abridged) Active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.
Duration of consent: All batches of the product imported or supplied until 3 October 2024.
Reason for consent: Availability of the product for importation and supply in Australia as soon as possible will assist in the management of the COVID-19 pandemic in Australia, and the preparation and application of labels for the product that set out the registration number would delay the timely availability of the product in Australia for that purpose. Accordingly, this consent will assist in facilitating the timely availability of the product in Australia and is therefore necessarily in the public interest.
COMIRNATY Omicron XBB.1.5 (raxtozinameran) COVID-19 VACCINE 10 micrograms/0.3 mL suspension for injection single dose vial
AUST number: 419371
Prescription medicine
Sponsor: Pfizer Australia Pty Ltd
Supply/import: Import and supply
Indication (abridged) Active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.
Duration of consent: All batches of the product imported or supplied until 3 October 2024.
Reason for consent: Availability of the product for importation and supply in Australia as soon as possible will assist in the management of the COVID-19 pandemic in Australia, and the preparation and application of labels for the product that set out the registration number would delay the timely availability of the product in Australia for that purpose. Accordingly, this consent will assist in facilitating the timely availability of the product in Australia, and is therefore necessarily in the public interest.
SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5 (elasomeran/davesomeran) COVID-19 VACCINE 0.1 mg/mL suspension for injection vial
AUST number: 399552
Prescription medicine
Sponsor: Moderna Australia Pty Ltd
Supply/import: Import and supply
Indication (abridged) Active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.
Duration of consent: All batches of the product imported or supplied until 17 February 2024.
Reason for consent: Availability of the product for importation and supply in Australia as soon as possible will assist in the management of the COVID-19 pandemic in Australia, and the preparation and application of labels for the product that set out the registration number would delay the timely availability of the product in Australia for that purpose. Accordingly, this consent will assist in facilitating the timely availability of the product in Australia, and is therefore necessarily in the public interest.
SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5 (elasomeran/davesomeran) COVID-19 VACCINE 0.1 mg/mL suspension for injection pre-filled syringe
AUST number: 399553
Prescription medicine
Sponsor: Moderna Australia Pty Ltd
Supply/import: Import and supply
Indication (abridged) Active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.
Duration of consent: All batches of the product imported or supplied until 17 February 2024.
Reason for consent: Availability of the product for importation and supply in Australia as soon as possible will assist in the management of the COVID-19 pandemic in Australia, and the preparation and application of labels for the product that set out the registration number would delay the timely availability of the product in Australia for that purpose. Accordingly, this consent will assist in facilitating the timely availability of the product in Australia, and is therefore necessarily in the public interest.
PAXLOVID nirmatrelvir 150 mg tablet and ritonavir 100 mg tablet blister composite pack
AUST number: 377572
Prescription medicine
Sponsor: Pfizer Australia Pty Ltd
Supply/import: Import and supply
Indication (abridged) Treatment of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.
Duration of consent: All batches of the product imported or supplied until 18 January 2024.
Reason for consent: Availability of the product for importation and supply in Australia as soon as possible will assist in the management of the COVID-19 pandemic in Australia, and the preparation and application of labels for the product that set out the registration number would delay the timely availability of the product in Australia for that purpose. Accordingly, this consent will assist in facilitating the timely availability of the product in Australia, and is therefore necessarily in the public interest.
PAXLOVID nirmatrelvir 150 mg tablet and ritonavir 100 mg tablet blister composite pack
AUST number: 389801
Prescription medicine
Sponsor: Pfizer Australia Pty Ltd
Supply/import: Import and supply
Indication Treatment of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.
Duration of consent: All batches of the product imported or supplied until 18 January 2024.
Reason for consent: Availability of the product for importation and supply in Australia as soon as possible will assist in the management of the COVID-19 pandemic in Australia, and the preparation and application of labels for the product that set out the registration number would delay the timely availability of the product in Australia for that purpose. Accordingly, this consent will assist in facilitating the timely availability of the product in Australia, and is therefore necessarily in the public interest.
COMIRNATY ORIGINAL/OMICRON BA.4-5 tozinameran/famtozinameran 15/15 micrograms/0.3 mL suspension for injection vial
AUST number: 400874
Prescription medicine
Sponsor: Pfizer Australia Pty Ltd
Supply/import: Import and supply
Indication (abridged) Active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.
Duration of consent: All batches of the product imported or supplied until 20 January 2024.
Reason for consent: Availability of the product for importation and supply in Australia as soon as possible will assist in the management of the COVID-19 pandemic in Australia, and the preparation and application of labels for the product that set out the registration number would delay the timely availability of the product in Australia for that purpose. Accordingly, this consent will assist in facilitating the timely availability of the product in Australia, and is therefore necessarily in the public interest.
SPIKEVAX BIVALENT ORIGINAL/OMICRON elasomeran and imelasomeran COVID-19 VACCINE 0.1 mg/mL suspension for injection pre-filled syringe
AUST number: 396452
Prescription medicine
Sponsor: Moderna Australia Pty Ltd
Supply/import: Import and supply
Indication (abridged) Active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.
Duration of consent: All batches of the product imported or supplied until 31 August 2023.
Reason for consent: Availability of the product for importation and supply in Australia as soon as possible will assist in the management of the COVID-19 pandemic in Australia, and the preparation and application of labels for the product that set out the registration number would delay the timely availability of the product in Australia for that purpose. Accordingly, this consent will assist in facilitating the timely availability of the product in Australia, and is therefore necessarily in the public interest.
LAGEVRIO molnupiravir 200 mg capsules bottle
AUST number: 372650
Prescription medicine
Sponsor: Merck Sharp & Dohme (Australia) Pty Ltd
Supply/import: Import and supply
Indication (abridged) Treatment of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.
Duration of consent: All batches of the product imported or supplied until 19 January 2024.
Reason for consent: Availability of the product for importation and supply in Australia as soon as possible will assist in the management of the COVID-19 pandemic in Australia, and the preparation and application of labels for the product that set out the registration number would delay the timely availability of the product in Australia for that purpose. Accordingly, this consent will assist in facilitating the timely availability of the product in Australia, and is therefore necessarily in the public interest.
EVUSHELD tixagevimab 100 mg/mL and cilgavimab 100 mg/mL solution for injection in 150 mg single dose vials
AUST number: 378245
Prescription medicine
Sponsor: AstraZeneca Pty Ltd
Supply/import: Import and supply
Indication (abridged) Treatment or prevention (or both) of coronavirus disease 2019 (COVID 19) caused by SARS-CoV-2.
Duration of consent: All batches of the product imported or supplied until 31 December 2023.
Reason for consent: Availability of the product for importation and supply in Australia as soon as possible will assist in the management of the COVID-19 pandemic in Australia, and the preparation and application of labels for the product that set out the registration number would delay the timely availability of the product in Australia for that purpose. Accordingly, this consent will assist in facilitating the timely availability of the product in Australia, and is therefore necessarily in the public interest.
NUVAXOVID (SARS-CoV-2 rS [NVX-CoV2373]) COVID-19 VACCINE adjuvanted suspension for injection vial
AUST number: 355139
Prescription medicine
Sponsor: Biocelect Pty Ltd
Supply/import: Import and supply
Indication (abridged) Active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.
Duration of consent: All batches of the product imported or supplied until 19 January 2024.
Reason for consent: Availability of the product for importation and supply in Australia as soon as possible will assist in the management of the COVID-19 pandemic in Australia, and the preparation and application of labels for the product that set out the registration number would delay the timely availability of the product in Australia for that purpose. Accordingly, this consent will assist in facilitating the timely availability of the product in Australia, and is therefore necessarily in the public interest.
COMIRNATY ORIGINAL/OMICRON BA.1 tozinameran/riltozinameran 30 mcg/0.3 mL suspension for injection vial
AUST number: 394890
Prescription medicine
Sponsor: Pfizer Australia Pty Ltd
Supply/import: Import and supply
Indication (abridged) Active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.
Duration of consent: All batches of the product imported or supplied until 31 October 2023.
Reason for consent: Availability of the product for importation and supply in Australia as soon as possible will assist in the management of the COVID-19 pandemic in Australia, and the preparation and application of labels for the product that set out the registration number would delay the timely availability of the product in Australia for that purpose. Accordingly, this consent will assist in facilitating the timely availability of the product in Australia, and is therefore necessarily in the public interest.
COMIRNATY (tozinameran) COVID-19 VACCINE 3 micrograms/0.2 mL concentrated suspension for injection vial
AUST number: 393433
Prescription medicine
Sponsor: Pfizer Australia Pty Ltd
Supply/import: Import and supply
Indication (abridged) Active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.
Duration of consent: All batches of the product imported or supplied until 30 September 2023.
Reason for consent: Availability of the product for importation and supply in Australia as soon as possible will assist in the management of the COVID-19 pandemic in Australia, and the preparation and application of labels for the product that set out the registration number would delay the timely availability of the product in Australia for that purpose. Accordingly, this consent will assist in facilitating the timely availability of the product in Australia, and is therefore necessarily in the public interest.
SPIKEVAX BIVALENT ORIGINAL/OMICRON elasomeran and imelasomeran COVID-19 VACCINE 0.1 mg/mL suspension for injection vial
AUST number: 389513
Prescription medicine
Sponsor: Moderna Australia Pty Ltd
Supply/import: Import and supply
Indication (abridged) Active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.
Duration of consent: All batches of the product imported or supplied until 31 August 2023.
Reason for consent: Availability of the product for importation and supply in Australia as soon as possible will assist in the management of the COVID-19 pandemic in Australia, and the preparation and application of labels for the product that set out the registration number would delay the timely availability of the product in Australia for that purpose. Accordingly, this consent will assist in facilitating the timely availability of the product in Australia, and is therefore necessarily in the public interest.
PAXLOVID nirmatrelvir 150 mg tablet and ritonavir 100 mg tablet blister composite pack
AUST number: 389801
Prescription medicine
Sponsor:Pfizer Australia Pty Ltd
Supply/import: Import and supply
Indication Treatment of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.
Duration of consent: All batches of the product imported or supplied until 17 January 2023.
Reason for consent: Availability of the product for importation and supply in Australia as soon as possible will assist in the management of the COVID-19 pandemic in Australia, and the preparation and application of labels for the product that set out the registration number would delay the timely availability of the product in Australia for that purpose. Accordingly, this consent will assist in facilitating the timely availability of the product in Australia, and is therefore necessarily in the public interest.
SPIKEVAX elasomeran COVID-19 Vaccine 0.1 mg/mL suspension for injection pre-filled syringe
AUST number:388245
Prescription medicine
Sponsor: Moderna Australia Pty Ltd
Supply/import: Import and supply
Indication Active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.
Duration of consent: All batches of the product imported or supplied until 31 July 2023.
Reason for consent: Availability of the product for importation and supply in Australia as soon as possible will assist in the management of the COVID-19 pandemic in Australia, and the preparation and application of labels for the product which set out the registration number would delay the timely availability of the product in Australia for that purpose. Accordingly, this consent will assist in facilitating the timely availability of the product in Australia, and is therefore necessarily in the public interest.
SPIKEVAX elasomeran COVID-19 Vaccine 0.1 mg/mL suspension for injection vial
AUST number: 388244
Prescription medicine
Sponsor: Moderna Australia Pty Ltd
Supply/import: Import and supply
Indication Active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.
Duration of consent: All batches of the product imported or supplied until 31 July 2023.
Reason for consent: Availability of the product for importation and supply in Australia as soon as possible will assist in the management of the COVID-19 pandemic in Australia, and the preparation and application of labels for the product which set out the registration number would delay the timely availability of the product in Australia for that purpose. Accordingly, this consent will assist in facilitating the timely availability of the product in Australia, and is therefore necessarily in the public interest.
SPIKEVAX elasomeran COVID-19 Vaccine 0.2 mg/mL suspension for injection vial
AUST number: 370599
Prescription medicine
Sponsor: Moderna Australia Pty Ltd
Supply/import: Import and supply
Indication Active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.
Duration of consent: All batches of the product imported or supplied until 31 July 2023.
Reason for consent: Availability of the product for importation and supply in Australia as soon as possible will assist in the management of the COVID-19 pandemic in Australia, and the preparation and application of labels for the product which set out the registration number would delay the timely availability of the product in Australia for that purpose. Accordingly, this consent will assist in facilitating the timely availability of the product in Australia, and is therefore necessarily in the public interest.
XEVUDY sotrovimab 500 mg/8 mL concentrated injection solution for infusion, vial
AUST number: 364110
Prescription medicine
Sponsor: GlaxoSmithKline Australia Pty Ltd
Supply/import: Import and supply
Indication Treatment of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.
Duration of consent: All batches of the product imported or supplied until 31 January 2023.
Reason for consent: Availability of the product for importation and supply in Australia as soon as possible will assist in the management of the COVID-19 pandemic in Australia, and the preparation and application of labels for the product which set out the registration number would delay the timely availability of the product in Australia for that purpose. Accordingly, this consent will assist in facilitating the timely availability of the product in Australia, and is therefore necessarily in the public interest.
EVUSHELD tixagevimab 100 mg/mL and cilgavimab 100 mg/mL solution for injection in 150 mg single dose vials
AUST number: 378245
Prescription medicine
Sponsor: AstraZeneca Pty Ltd
Supply/import: Import and supply
Indication (abridged): Treatment or prevention (or both) of coronavirus disease 2019 (COVID 19) caused by SARS-CoV-2.
Duration of consent: All batches of the product imported or supplied until 28 February 2023.
Reason for consent: Availability of the product for importation and supply in Australia as soon as possible will assist in the management of the COVID-19 pandemic in Australia, and the preparation and application of labels for the product that set out the registration number would delay the timely availability of the product in Australia for that purpose. Accordingly, this consent will assist in facilitating the timely availability of the product in Australia, and is therefore necessarily in the public interest.
NUVAXOVID (SARS-CoV-2 rS [NVX-CoV2373]) COVID-19 VACCINE adjuvanted suspension for injection vial
AUST number: 355139
Prescription medicine
Sponsor: Biocelect Pty Ltd
Supply/import: Import and supply
Indication (abridged): Active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.
Duration of consent: All batches of the product imported or supplied until 20 January 2023.
Reason for consent: Availability of the product for importation and supply in Australia as soon as possible will assist in the management of the COVID-19 pandemic in Australia, and the preparation and application of labels for the product that set out the registration number would delay the timely availability of the product in Australia for that purpose. Accordingly, this consent will assist in facilitating the timely availability of the product in Australia, and is therefore necessarily in the public interest.
PAXLOVID nirmatrelvir 150 mg tablet and ritonavir 100 mg tablet blister composite pack
AUST number: 377572
Prescription medicine
Sponsor: Pfizer Australia Pty Ltd
Supply/import: Import and supply
Indication (abridged): Treatment of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.
Duration of consent: All batches of the product imported or supplied until 18 January 2023.
Reason for consent: Availability of the product for importation and supply in Australia as soon as possible will assist in the management of the COVID-19 pandemic in Australia, and the preparation and application of labels for the product that set out the registration number would delay the timely availability of the product in Australia for that purpose. Accordingly, this consent will assist in facilitating the timely availability of the product in Australia, and is therefore necessarily in the public interest.
LAGEVRIO molnupiravir 200 mg capsules bottle
AUST number: 372650
Prescription medicine
Sponsor: Merck Sharp & Dohme (Australia) Pty Ltd
Supply/import: Import and supply
Indication (abridged): Treatment of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.
Duration of consent: All batches of the product imported or supplied until 18 January 2023.
Reason for consent: Availability of the product for importation and supply in Australia as soon as possible will assist in the management of the COVID-19 pandemic in Australia, and the preparation and application of labels for the product that set out the registration number would delay the timely availability of the product in Australia for that purpose. Accordingly, this consent will assist in facilitating the timely availability of the product in Australia, and is therefore necessarily in the public interest.
COMIRNATY (tozinameran [mRNA]) COVID-19 VACCINE 30 micrograms/0.3 mL concentrated suspension for injection vial
AUST number: 346290
Prescription medicine
Sponsor: Pfizer Australia Pty Ltd
Supply/import: Import and supply
Indication (abridged): Active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.
Duration of consent: All batches of the product imported or supplied until 8 December 2022.
Reason for consent: Availability of the product for importation and supply in Australia as soon as possible will assist in the management of the COVID-19 pandemic in Australia, and the preparation and application of labels for the product that set out the registration number would delay the timely availability of the product in Australia for that purpose. Accordingly, this consent will assist in facilitating the timely availability of the product in Australia, and is therefore necessarily in the public interest.
COMIRNATY (tozinameran [mRNA]) COVID-19 VACCINE 30 micrograms/0.3 mL suspension for injection vial
AUST number: 377110
Prescription medicine
Sponsor: Pfizer Australia Pty Ltd
Supply/import: Import and supply
Indication (abridged): Active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.
Duration of consent: All batches of the product imported or supplied until 8 December 2022.
Reason for consent: Availability of the product for importation and supply in Australia as soon as possible will assist in the management of the COVID-19 pandemic in Australia, and the preparation and application of labels for the product that set out the registration number would delay the timely availability of the product in Australia for that purpose. Accordingly, this consent will assist in facilitating the timely availability of the product in Australia, and is therefore necessarily in the public interest.
COMIRNATY (tozinameran [mRNA]) COVID-19 VACCINE 10 micrograms/0.2 mL concentrated suspension for injection vial
AUST number: 377111
Prescription medicine
Sponsor: Pfizer Australia Pty Ltd
Supply/import: Import and supply
Indication (abridged): Active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.
Duration of consent: All batches of the product imported or supplied until 8 December 2022.
Reason for consent: Availability of the product for importation and supply in Australia as soon as possible will assist in the management of the COVID-19 pandemic in Australia, and the preparation and application of labels for the product that set out the registration number would delay the timely availability of the product in Australia for that purpose. Accordingly, this consent will assist in facilitating the timely availability of the product in Australia, and is therefore necessarily in the public interest.
RONAPREVE casirivimab 120 mg/mL and imdevimab 120 mg/mL solutions for infusion or injection in 300 mg single dose vials
AUST number: 373839
Prescription medicine
Sponsor: Roche Products Pty Ltd
Supply/import: Import and supply
Indication (abridged): Treatment of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.
Duration of consent: All batches of the product imported or supplied until 15 October 2022.
Reason for consent: Availability of the product for importation and supply in Australia as soon as possible will assist in the management of the COVID-19 pandemic in Australia, and the preparation and application of labels for the product which set out the registration number would delay the timely availability of the product in Australia for that purpose. Accordingly, this consent will assist in facilitating the timely availability of the product in Australia, and is therefore necessarily in the public interest.
RONAPREVE casirivimab 120 mg/mL and imdevimab 120 mg/mL solutions for infusion or injection in 1332 mg multi dose vials
AUST number: 374310
Prescription medicine
Sponsor: Roche Products Pty Ltd
Supply/import: Import and supply
Indication (abridged): Treatment of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.
Duration of consent: All batches of the product imported or supplied until 15 October 2022.
Reason for consent: Availability of the product for importation and supply in Australia as soon as possible will assist in the management of the COVID-19 pandemic in Australia, and the preparation and application of labels for the product which set out the registration number would delay the timely availability of the product in Australia for that purpose. Accordingly, this consent will assist in facilitating the timely availability of the product in Australia, and is therefore necessarily in the public interest.
VEKLURY remdesivir 100 mg powder for injection vial
AUST number: 338419
Prescription medicine
Sponsor: Gilead Sciences Pty Ltd
Supply/import: Import and supply
Indication (abridged): Treatment of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.
Duration of consent: All batches of the product imported or supplied until 10 July 2022.
Reason for consent: Availability of the product for importation and supply in Australia as soon as possible will assist in the management of the COVID-19 pandemic in Australia, and the preparation and application of labels for the product which set out the registration number would delay the timely availability of the product in Australia for that purpose. Accordingly, this consent will assist in facilitating the timely availability of the product in Australia, and is therefore necessarily in the public interest.
XEVUDY sotrovimab 500 mg/8 mL concentrated injection solution for infusion, vial
AUST number: 364110
Prescription medicine
Sponsor: GlaxoSmithKline Australia Pty Ltd
Supply/import: Import and supply
Indication(abridged): Treatment of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.
Duration of consent: All batches of the product imported or supplied until 17 August 2022.
Reason for consent: Availability of the product for importation and supply in Australia as soon as possible will assist in the management of the COVID-19 pandemic in Australia, and the preparation and application of labels for the product which set out the registration number would delay the timely availability of the product in Australia for that purpose. Accordingly, this consent will assist in facilitating the timely availability of the product in Australia, and is therefore necessarily in the public interest.
SPIKEVAX elasomeran COVID-19 Vaccine 0.2 mg/mL suspension for injection vial
AUST number: 370599
Prescription medicine
Sponsor: Moderna Australia Pty Ltd
Supply/import: Import and supply
Indication (abridged): Active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.
Duration of consent: All batches of the product imported or supplied until 30 July 2022.
Reason for consent: Availability of the product for importation and supply in Australia as soon as possible will assist in the management of the COVID-19 pandemic in Australia, and the preparation and application of labels for the product which set out the registration number would delay the timely availability of the product in Australia for that purpose. Accordingly, this consent will assist in facilitating the timely availability of the product in Australia, and is therefore necessarily in the public interest.
COMIRNATY (BNT162b2 [mRNA]) COVID-19 VACCINE 30 micrograms/0.3 mL concentrated suspension for injection vial
AUST number: 346290
Prescription medicine
Sponsor: Pfizer Australia Pty Ltd
Supply/import: Import and supply
Indication (abridged): Active immunisation to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.
Duration of consent: All batches of the product imported or supplied until 24 January 2022
Reason for consent: Availability of the product for importation and supply in Australia as soon as possible will assist in the management of the COVID-19 pandemic in Australia, and the preparation and application of labels for the product that set out the registration number would delay the timely availability of the product in Australia for that purpose. Accordingly, this consent will assist in facilitating the timely availability of the product in Australia, and is therefore necessarily in the public interest.
COVID-19 Vaccine AstraZeneca (ChAdOx1-S) solution for injection 5mL multidose vial
AUST number: 349072
Prescription medicine
Sponsor: AstraZeneca Pty Ltd
Supply/import: Import and supply
Indication (abridged): Active immunisation for the prevention of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.
Duration of consent: All batches of the product imported or supplied until 15 February 2022
Reason for consent: Availability of the product for importation and supply in Australia as soon as possible will assist in the management of the COVID-19 pandemic in Australia, and the preparation and application of labels for the product that set out the registration number would delay the timely availability of the product in Australia for that purpose. Accordingly, this consent will assist in facilitating the timely availability of the product in Australia, and is therefore necessarily in the public interest.